SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain

J Hepatol. 2020 Nov;73(5):1262-1263. doi: 10.1016/j.jhep.2020.07.007. Epub 2020 Jul 13.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antiviral Agents* / therapeutic use
  • Benzimidazoles
  • Betacoronavirus
  • COVID-19
  • Carbamates
  • Coronavirus Infections*
  • Drug Repositioning
  • Fluorenes
  • Hepatitis B virus
  • Hepatitis C* / drug therapy
  • Hepatitis C* / epidemiology
  • Heterocyclic Compounds, 4 or More Rings
  • Humans
  • Pandemics*
  • Peptide Hydrolases
  • Pneumonia, Viral*
  • SARS-CoV-2
  • Severe acute respiratory syndrome-related coronavirus*
  • Spain / epidemiology

Substances

  • Antiviral Agents
  • Benzimidazoles
  • Carbamates
  • Fluorenes
  • Heterocyclic Compounds, 4 or More Rings
  • ledipasvir
  • Peptide Hydrolases
  • velpatasvir